Results 121 to 130 of about 2,895 (208)

Randomized Clinical Trial of Sevelamer Carbonate on Serum Klotho and Fibroblast Growth Factor 23 in CKD. [PDF]

Clin J Am Soc Nephrol, 2017
Liabeuf S, Ryckelynck JP, El Esper N, Ureña P, Combe C, Dussol B, Fouque D, Vanhille P, Frimat L, Thervet E, Mentaverri R, Prié D, Choukroun G, FRENCH Study collaborators.   +13 more
europepmc   +1 more source

Vascular Calcification in Patients with Chronic Kidney Disease: Types, Clinical Impact and Pathogenesis [PDF]

, 2011
Cabezas Rodríguez, Iván, Cannata Andía, Jorge Benito, Díaz López, José Bernardino, López Ongil, Susana, Rodríguez García, Minerva, Román García, Pablo   +5 more
core   +1 more source

Short-term effects of sevelamer-carbonate on fibroblast growth factor 23 and pulse wave velocity in patients with normophosphataemic chronic kidney disease Stage 3. [PDF]

Clin Kidney J, 2019
Bouma-de Krijger A, van Ittersum FJ, Hoekstra T, Ter Wee PM, Vervloet MG.   +4 more
europepmc   +1 more source

Characteristics of Patients Who Achieve Serum Phosphorus Control on Sucroferric Oxyhydroxide or Sevelamer Carbonate: A post hoc Analysis of a Phase 3 Study.

Nephron, 2020
Covic AC, Sprague SM, Rastogi A, Ketteler M, Walpen S, Perrin A, Floege J.   +6 more
europepmc   +1 more source

Sevelamer Carbonate and Lanthanum Usage Evaluation and Cost Considerations at a Veteran's Affairs Medical Center. [PDF]

Hosp Pharm, 2016
Robison R, Cooney D, Low MB, Desai N.
europepmc   +1 more source

Sevelamer carbonate reduces the risk of hypomagnesemia in hemodialysis-requiring end-stage renal disease patients. [PDF]

Clin Kidney J, 2016
Rosa-Diez G, Negri AL, Crucelegui MS, Philippi R, Perez-Teysseyre H, Sarabia-Reyes C, Loor-Navarrete H, Heguilen R.   +7 more
europepmc   +1 more source

An overview on adynamic bone disease clinical and therapeutical approaches [PDF]

, 2015
Mariana Barata Santos Barreira de Jesus
core  

Mineral bone disorders (MBD) in patients on peritoneal dialysis [PDF]

, 2019
HANAFUSA Norio, NITTA Kosaku, TSUCHIYA Ken   +2 more
core   +2 more sources

Potentially modifiable factors associated with non-adherence to phosphate binder use in patients on hemodialysis [PDF]

, 2013

core   +1 more source

Effects of sevelamer carbonate on advanced glycation end products and antioxidant/pro-oxidant status in patients with diabetic kidney disease. [PDF]

Clin J Am Soc Nephrol, 2015
Yubero-Serrano EM, Woodward M, Poretsky L, Vlassara H, Striker GE, AGE-less Study Group.   +5 more
europepmc   +1 more source